RJA
ABCL icon

Raymond James & Associates’s AbCellera Biologics ABCL Stock Holding History

Raymond James & Associates’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$32.4K Sell
12,458
-1,111
-8% -$3.08K ﹤0.01% 3901
2024
Q2 		$40.2K Sell
13,569
-105
-0.8% -$397 ﹤0.01% 3817
2024
Q1 		$61.9K Buy
13,674
+1,288
+10% +$6.57K ﹤0.01% 3783
2023
Q4 		$70.7K Sell
12,386
-3,746
-23% -$17.4K ﹤0.01% 3675
2023
Q3 		$74.2K Sell
16,132
-36,692
-69% -$223K ﹤0.01% 3643
2023
Q2 		$341K Buy
52,824
+5,691
+12% +$38.8K ﹤0.01% 3166
2023
Q1 		$355K Buy
47,133
+26,744
+131% +$243K ﹤0.01% 3135
2022
Q4 		$207K Sell
20,389
-2,076
-9% -$24K ﹤0.01% 3436
2022
Q3 		$222K Buy
22,465
+4,287
+24% +$47K ﹤0.01% 3380
2022
Q2 		$194K Buy
18,178
+2,186
+14% +$18.5K ﹤0.01% 3515
2022
Q1 		$156K Sell
15,992
-56,734
-78% -$537K ﹤0.01% 3733
2021
Q4 		$1.04M Sell
72,726
-53,625
-42% -$814K ﹤0.01% 2593
2021
Q3 		$2.53M Buy
126,351
+7,448
+6% +$132K ﹤0.01% 1933
2021
Q2 		$2.62M Buy
118,903
+46,007
+63% +$1.27M ﹤0.01% 1908
2021
Q1 		$2.48M Buy
+72,896
New +$2.9M ﹤0.01% 1869

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Raymond James & Associates's ABCL Position: Q3 2024 in Review

Raymond James & Associates reduced its AbCellera Biologics (ABCL) stake by 8.2% in Q3 2024, selling an estimated $3.08K and leaving 12,458 shares worth $32.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3901.

Raymond James & Associates first reported a position in ABCL in Q1 2021 and has held it in 15 quarters since. The position peaked at $2.62M in Q2 2021. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Raymond James & Associates held 12,458 shares of AbCellera Biologics worth $32.4K as of Q3 2024.
  • Raymond James & Associates sold 1,111 AbCellera Biologics shares in Q3 2024, an estimated $3.08K.
  • AbCellera Biologics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3901 holding.
  • Raymond James & Associates first reported a position in AbCellera Biologics in Q1 2021 and has held it in 15 quarters since.
  • Raymond James & Associates's AbCellera Biologics position peaked at $2.62M in Q2 2021.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.